Skip to main content

Duration of Follow Up for New Molecular Entities Approved in 2019: Third Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
new molecular entities (NMEs)
Description

In this analysis, we characterized dispensing and administration patterns of 48 New Molecular Entities (NMEs) approved from January 1, 2019 to December 31, 2019, stratified by age and sex in the Sentinel Distributed Database (SDD).

This analysis is a re-run of a previous analysis, Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis.

This analysis includes two reports:

  • Report 1: This report characterizes the 26 New Molecular Entities (NMEs) approved from January 1, 2019 to August 31, 2019. The study period includes data from January 1, 2019 to December 31, 2024. We distributed this request to 13 Sentinel Data Partners on May 22, 2025.
  • Report 2: This report characterizes the 22 New Molecular Entities (NMEs) approved from September 1, 2019 to December 31, 2019. The study period includes data from January 1, 2019 to December 31, 2024. We distributed this request to 13 Sentinel Data Partners on May 22, 2025.
Deliverables (2)
Sentinel Modular Program Report: Duration of Follow Up for New Molecular Entities Approved in 2019: Third Descriptive Analysis, Report 1 Sentinel Modular Program Report: Duration of Follow Up for New Molecular Entities Approved in 2019: Third Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2019 - December 31, 2024
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: New Molecular Entities (NMEs) & Utilization Characterization